Allergen-specific immunotherapy is a clinically proven effective treatment for many allergic diseases including asthma, however, it is not currently available for latex allergy due to the high risk of anaphylaxis. There is therefore a crucial need for an animal model of latex allergy in which to develop effective immunotherapy. Previous mouse models of latex allergy either did not characterise the allergic pulmonary immune response, or used crude latex extracts, making it difficult to quantify the contribution of individual proteins and limiting their usefulness for developing specific immunotherapy. We immunised mice with recombinant Hev b 5, a defined major latex allergen, or latex glove protein extract, representing the range of occupationally-encountered processed latex allergens. The immune response was compared to that seen in ovalbumin-immunised mice. Immunisation with Hev b 5 or glove extract elicits hallmarks of allergic pulmonary Th2-type immune responses, comparable to those for ovalbumin, including: (1) serum antigen-specific IgE, (2) an eosinophilic inflammatory infiltrate in the lung, (3) increased IL-5 in lung bronchoalveolar lavage fluid, and (4) mucus hypersecretion by epithelial cells in the lung airways. This mouse model will aid the development of potentially curative treatments for latex-sensitised individuals including those with occupational asthma.